Lundbeck's schizophrenia treatment for teenagers receives FDA priority review status

Lundbeck and partner Otsuka have completed a supplemental drug application for the FDA to expand the use of schizophrenia drug Rexulti, one year earlier than expected.

Photo: Thomas Borberg

In December, Lundbeck and its partner Otsuka could potentially see the indication of their treatmeant of schizophrenia, Rexulti, expanded to include an important patient group in the US.

The US Food and Drug Administration (FDA) has confirmed that the vetting work for the drug has begun, after the two companies asked to include patients as young as 13 years old in a supplemental application. Today, the drug is only approved for the treatment of adults with schizophrenia, in addition to its adjunctive therapy for in adults with major depressive disorder.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs